Drugs / TransCon hGH
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04326374 | Dec 2019 → Apr 2022 | anterior pituitary gland disorder, pituitary deficiency | Visen Pharmaceuticals (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03344458 | Dec 2017 → Feb 2023 | pituitary deficiency, pituitary gland disorder | Ascendis Pharma A/S | Completed | No outcome recorded |
| Phase 3 | NCT03305016 | Nov 2017 → Mar 2019 | pituitary deficiency, pituitary gland disorder | Ascendis Pharma Endocrinology Division A/S | Completed | No outcome recorded |
| Phase 3 | NCT02781727 | Dec 2016 → Jan 2019 | pituitary deficiency | Ascendis Pharma Endocrinology Division A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TransCon hGH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02781727 ↗ |
| Known as | lonapegsomatropin | “Lonapegsomatropin (TransCon hGH) is an investigational long-acting, once-weekly prodrug for the treatment of GHD.” PMID 34272849 ↗ Oct 2021 |
| Modality | Protein / enzyme biologic | “TransCon hGH, a long-acting growth hormone product” NCT02781727 ↗ |
| Route | Subcutaneous | “Once weekly subcutaneous injection of TransCon hGH” NCT02781727 ↗ |